What is LOPJLB’s current signal on ANIX?

LOPJLB’s latest quantitative signal on Anixa Biosciences, Inc. (ANIX) is BUY in a CRISIS regime. Signals are updated daily.

What market regime is ANIX in?

Anixa Biosciences, Inc. (ANIX) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Anixa Biosciences, Inc. (ANIX) do?

Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation…

Anixa Biosciences, Inc. (ANIX)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$2.67-5.99%Close

BUYCRISIS · day 1

Company news

prnewswire.com · 19h ago

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

prnewswire.com · 9d ago

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

prnewswire.com · 13d ago

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

defenseworld.net · 16d ago

Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Arnold Baskies Purchases 5,000 Shares

defenseworld.net · 16d ago

Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Buys $19,460.00 in Stock

prnewswire.com · 23d ago

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

prnewswire.com · 28d ago

Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board

prnewswire.com · 35d ago

Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

prnewswire.com · 41d ago

Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026

prnewswire.com · 51d ago

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

prnewswire.com · 57d ago

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

zacks.com · 84d ago

Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know

zacks.com · 84d ago

New Strong Buy Stocks for July 22nd

prnewswire.com · 92d ago

Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology

Market news & ticker search · RSS for ANIX

FAQ

What is LOPJLB’s current signal on ANIX?: LOPJLB’s latest quantitative signal on Anixa Biosciences, Inc. (ANIX) is BUY in a CRISIS regime. Signals are updated daily.
What market regime is ANIX in?: Anixa Biosciences, Inc. (ANIX) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Anixa Biosciences, Inc. (ANIX) do?: Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation…

Anixa Biosciences, Inc. (ANIX)

Key stats

Prediction markets

Company news

FAQ